OBJECTIVES This study sought to report the results of a prospective randomized controlled trial comparing paclitaxelcoated balloons (PCB) versus drug-eluting stents (DES) in long infrapopliteal lesions.
E ndovascular treatment is increasingly being used as the preferred method of revascularization in patients with infrapopliteal arterial disease suffering from critical limb ischemia (CLI). Compared with surgical bypass, which can be technically challenging or not offered at all because of underlying comorbidities of CLI patients, angioplasty of the crural arteries is able to achieve multivessel recanalization to the foot in a safer and less invasive way (1) (2) (3) .
Traditional plain balloon angioplasty has long been the gold standard endovascular therapy in the infrapopliteal field, accompanied by bare-metal stents as a bailout choice (4, 5) . Nearly a decade ago, certain investigators foresaw the advantages of using drugeluting stents (DES) in the infrapopliteal region (6) (7) (8) (9) . Since then, 3 multicenter randomized controlled trials and a meta-analysis have confirmed the superiority of DES in terms of inhibiting restenosis, reducing target lesion revascularization (TLR, and improving event-free survival, thereby providing level IA evidence for their use in short infrapopliteal lesions (10) (11) (12) (13) .
On the other hand, paclitaxel-coated balloons (PCB) have already been shown to have superior results with less vascular restenosis and fewer TLR events than with plain balloon angioplasty when used in the superficial femoral artery and in failing arteriovenous fistulas (14, 15) . Recently, a single-arm and 2 randomized controlled trials provided evidence about improved outcomes with PCB in the treatment of infrapopliteal lesions, at 3, 6, and 12 months, compared with percutaneous transluminal angioplasty (16) (17) (18) .
CLI cases, especially diabetic ones, are typically characterized by long diffuse atherosclerotic lesions in about one-half of the cases (19) . To our knowledge, there is only 1 single-arm study testing plain balloon angioplasty in long infrapopliteal lesions, and evidence on the effectiveness of DES in long these lesions is also very scarce (20, 21) . On the other hand, the 2 randomized controlled trials reported application of PCB in relatively longer lesions. This trial was designed to explore the effectiveness of PCB versus DES specifically for the treatment of long infrapopliteal lesions that are more representative of routine practice in the treatment of CLI.
METHODS
STUDY DESIGN. The IDEAS (Infrapopliteal Drug-Eluting Angioplasty Versus Stenting) trial was designed to be a single-center randomized (1:1) controlled trial comparing PCB versus DES in long infrapopliteal lesions for the treatment of CLI. It was hypothesized that the 2 competing drug technologies would produce similar inhibition of neointimal hyperplasia (NIH); in other words, the null hypothesis was set at equivalence. The expected angiographic restenosis rate >50% at 6 months was estimated at 10% for both groups and the study was powered to exclude a difference between the 2 treatments of >25% (a ¼ 0.05 and statistical power set at 0.80). The number of patients required in each treatment arm was calculated to be 25. No allowance was made for dropouts. One-to-one randomization was computer generated and the method of sealed envelopes was used. The hospital's ethical and scientific committee approved the protocol. Written informed consent was acquired from all recruited subjects. The study was announced on a public database (NCT01517997) and was performed within standards of care without any financial support from industry or research grants.
PATIENT POPULATIONS. From December 1, 2011 to January 1st 2013, 73 patients were referred to our department for percutaneous revascularization of the infrapopliteal vessels due to intermittent claudication or CLI. After screening for potential enrollment in the trial, 23 patients were excluded in total (13 patients did not fulfill the inclusion criteria; 8 patients suffered from distal below-the-ankle disease; and 2 patients did not consent to be included in the study). Overall, 50 patients met the inclusion criteria, provided a signed informed consent form and were randomized to undergo either PCB angioplasty (PCB group) or DES placement (DES group) for the treatment of long infrapopliteal lesions (>70 mm in length, maximum of 2 arteries per limb) ( Figure 1) . In order to be included in the trial, patients had to suffer from severe leg ischemia (Rutherford classes 3-to 6) and to have $1 angiographically documented infrapopliteal lesion of >70 mm in length. On the other hand, distal arterial occlusive disease compromising below-the-ankle runoff of the target vessel to be treated (e.g., blocked dorsalis pedis in case of anterior tibial artery treatment or occluded plantar arteries in case of posterior tibial artery treatment) was the most important exclusion criterion ( Table 1) . Inflow iliofemoral occlusive disease was treated as necessary. 
RESULTS
Within 14 months, 50 patients were randomized (1:1)
to PCB or DES treatment of long infrapopliteal lesions.
The flow of the study is shown in the chart of Table 3 ).
In total, 44 angiograms were evaluable with QVA at 6 months ( Figure 2 (Figure 3 ). There were no significant differences with regard to TLR (13), there is no strong evidence to support their use in longer lesions (21) . Below-the-knee application of DES has been also hampered by cost issues because with current devices (the longest was significantly higher in the PCB group, but it was similar between both groups at 6 months. Note that positive remodeling with regression of the stenosis and negative late lumen loss was noted in a few PCB cases; however, binary restenosis was significantly higher in the PCB group than in the DES group. QVA ¼ quantitative vessel analysis; other abbreviations as in Figure 1 . available is 38 mm) multiple overlapping stents would be necessary for full coverage of any lesion >10 cm, raising procedural costs (22) . In addition, the expected increased difficulty to cross an occluded stent compared with a reoccluded native lesion previously treated with balloon angioplasty could be another factor to take into consideration during decision making for long infrapopliteal lesions. On the other hand, application of PCB devices has been received enthusiastically in the femoropopliteal arteries, and recently, promising results have also been shown in the below-the-knee arena (15) (16) (17) (18) .
The IDEAS trial is the first study to directly Table 2 ) or at 6 months ( Table 3) .
Abbreviations as in Figure 1 . Abbreviations as in Figure 1 . group with a rate of 27% versus 74% in the control group after 1 year (p < 0.001). Only 1 major amputation was reported out of 132 CLI patients corresponding to a limb salvage rate of nearly 100% in both groups (18) .
STUDY LIMITATIONS. The scientific evidence amassed and reported by the IDEAS randomized trial suffers from certain limitations. First, this was a single-center study and a relatively small number of patients with a low rate of CTO were recruited. Second, overall follow-up was limited to 6 months when a digital angiogram was performed for QVA purposes.
In addition, there was an absence of an independent core lab for the QVA analysis, but there was no commercial sponsor or other source of funding. The study was designed as an exploratory study for equivalence between DES and PCB and was appropriately powered only for the outcome of restenosis in order to compare NIH between the 2 treatments.
Hence, robust conclusions on long-term efficacy and clinical outcomes cannot be derived. upatras.gr.
CONCLUSIONS

